Within ARETHUSA, MMR-proficient CRC patient tumors are tested for MGMT expression by immunohistochemistry, and those that are negative (e.g., for MGMT promoter methylation) are treated with temozolomide and then tested for tumor mutational burden in post-temozolomide tumor biopsies. This evidence concerns the gene MGMT and colorectal carcinoma.